Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease

American Journal of Geriatric Psychiatry

Volumn 12, Issue 4, 2004, Pages 358-369

  Ritchie, Craig W ^a   Ames, David ^b   Clayton, Tim ^c   Lai, Rosalind ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMBASE; HUMAN; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 3042858052     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200407000-00003     Document Type: Article

References (36)

1. Davis P, Maloney J: Selective loss of central cholinergic neurons in Alzheimer's disease (letter). Lancet 1976; 2:1403
2. Minger SL, Esiri MM, McDonald B, et al: Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55:1460-1467
3. Cummings JL, Black C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6(suppll):S64-S78
4. U.S. Food and Drug Administration: Food, Drug, and Cosmetic Reports: FDA Guidance on Alzheimer's Drug Clinical Utility Assessments. Washington, DC. FDC Reports, 1992; pp 13-15
5. Birks JS, Harvey R: Donepezil for dementia due to Alzheimer's disease (Cochrane Review), in The Cochrane Library, Issue 2, 2004, Chichester, UK, Wiley
6. Olin J, Schneider L: Galanthamine for Alzheimer's disease. Cochrane Database of Systematic Reviews Issue 2, 2004, Wiley
7. Birks J, Grimely-Evans J, Iakovidou V, et al: Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2002; Issue 2
8. Qizilbash N, Birks JS, Lopez-Arrieta J, et al: Tacrine for Alzheimer's disease (Cochrane review), in The Cochrane Library, Issue 2, 2004, Chichester, UK, Wiley
9. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: a report on the NINCDS-ADRDA Work Group Under the Auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
10. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
11. Mohs RC, Doody RS, Morris JC, et al: A one-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57:481-488
12. Homma A, Imai Y, Hagiguchi S, et al: Late Phase II clinical study of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia. Clin Eval 1998; 26:251-284
13. Sramek JJ, Anand R, Wardle TS, et al: Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996; 58:1201-1207
14. Agid Y, Dubois B: Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res 1998; 59:837-845
15. Forette F, Anand R, Gharabawi G: A Phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). Eur J Neurology 1999; 6:423-429
16. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a U.S. multicentre, randomised, double-blind, placebo-controlled trial. Dementia 1996; 7:293-303
17. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50:136-145
18. Rogers SL, Doody RC, Mohs RC, et al: Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double blind, placebo-controlled study. Arch Intern Med 1998; 158:1021-1031
19. Burns A, Rossor M, Hecker J, et al: The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dementia Geriatr Cogn Disord 1999; 10:237-244
20. Homma A, Takeda M, Imai Y, et al: Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicentre, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord 2000; 11:299-313
21. Winblad B, Engedal K, Soininen H, et al: A one-year, randomized, placebo controlled study of donepezil in patients with mild-to-moderate AD. Neurology 2001; 57:489-495
22. Tariot PN, Cummings JL, Katz IR, et al: A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001; 49:1590-1599
23. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate-to-severe Alzheimer's disease. Neurology 2001; 57:613-620
24. Wilcock GK, Lilienfeld S, Gaens E: Efficacy and safety of galanthamine in patients with mild-to-moderate Alzheimer's disease: multicentre randomised, controlled trial. BMJ 2000; 321:1-7
25. Raskind MA, Peskind ER, Wessel T, et al: A six-month randomized, placebo-controlled trial with a six-month extension. Neurology 2000; 54:2261-2268
26. Tariot PN, Solomon PR, Morris JC, et al: A five-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54:2269-2276
27. Wilkinson D, Murray J: Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16:852-857
28. Rockwood K, Mintzer J, Truyen L, et al: Effects of a flexible galanthamine dose in AD: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71:589-595
29. Erkinjutti T, Kurz A, Gauthier S, et al: Efficacy of galanthamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283-1290
30. Corey-Bloom J, Anand R, Veach J: A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild-to-moderately severe AD. Int J Geriatr Psychopharmacol 1998; 1:55-65
31. Rosler M, Anand R, Cicin-Sain A, et al: Efficacy and safety of rivastigmine in patients with AD: international randomised controlled trial. BMJ 1999; 318:633-640
32. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975; 12:189-198
33. Hughes CP, Berg L, Danziger WL, et al: A new rating scale for the staging of dementia. Br J Psychiatry 1982; 141:1356-1364
34. Berg L, Miller JP, Baty J, et al: Mild senile dementia of the Alzheimer type: four evaluations of intervention. Ann Neurol 1992; 31:242-249
35. Bråne G, Gottfries CG, Winblad B: The GBS scale: validity, reliability and application in anti-dementia drug trials. Dement Geriatr Cogn Disord 2001; 12:1-14
36. Riley-McCarten J, Rottunda S, Kuskowski M: The Mini-Mental State Exam is not a sensitive measure of decline in Alzheimer's disease. Neurobiol Aging 2002;23(1S):S166, S620